CN102802635B - 麻醉药制剂 - Google Patents

麻醉药制剂 Download PDF

Info

Publication number
CN102802635B
CN102802635B CN201180013975.2A CN201180013975A CN102802635B CN 102802635 B CN102802635 B CN 102802635B CN 201180013975 A CN201180013975 A CN 201180013975A CN 102802635 B CN102802635 B CN 102802635B
Authority
CN
China
Prior art keywords
cyclodextrin
alfaxalone
anesthetic
rats
neuroactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180013975.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102802635A (zh
Inventor
朱丽叶·玛格丽特·古德柴尔德
科林·斯坦利·古德柴尔德
本杰明·詹姆斯·博伊德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goodchild Investments Pty Ltd
Original Assignee
Goodchild Investments Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goodchild Investments Pty Ltd filed Critical Goodchild Investments Pty Ltd
Publication of CN102802635A publication Critical patent/CN102802635A/zh
Application granted granted Critical
Publication of CN102802635B publication Critical patent/CN102802635B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180013975.2A 2010-01-21 2011-01-19 麻醉药制剂 Active CN102802635B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US61/297,249 2010-01-21
US38531810P 2010-09-22 2010-09-22
US61/385,318 2010-09-22
PCT/AU2011/000050 WO2011088503A1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Publications (2)

Publication Number Publication Date
CN102802635A CN102802635A (zh) 2012-11-28
CN102802635B true CN102802635B (zh) 2014-07-30

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180013975.2A Active CN102802635B (zh) 2010-01-21 2011-01-19 麻醉药制剂

Country Status (27)

Country Link
US (2) US8697678B2 (enExample)
EP (1) EP2525798B1 (enExample)
JP (1) JP5930311B2 (enExample)
KR (1) KR101747476B1 (enExample)
CN (1) CN102802635B (enExample)
AU (1) AU2011207103B2 (enExample)
BR (1) BR112012017800B1 (enExample)
CA (1) CA2786762C (enExample)
CL (1) CL2012002032A1 (enExample)
CY (1) CY1119947T1 (enExample)
DK (1) DK2525798T3 (enExample)
ES (1) ES2646829T3 (enExample)
GB (2) GB2484244B (enExample)
HR (1) HRP20171699T1 (enExample)
HU (1) HUE035441T2 (enExample)
LT (1) LT2525798T (enExample)
NO (1) NO2525798T3 (enExample)
NZ (1) NZ601255A (enExample)
PL (1) PL2525798T3 (enExample)
PT (1) PT2525798T (enExample)
RS (1) RS56576B1 (enExample)
RU (1) RU2574022C2 (enExample)
SG (1) SG181997A1 (enExample)
SI (1) SI2525798T1 (enExample)
SM (1) SMT201700518T1 (enExample)
WO (1) WO2011088503A1 (enExample)
ZA (1) ZA201205370B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631233C (en) 2005-11-28 2011-11-08 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
HRP20200567T1 (hr) * 2011-11-29 2020-06-26 Jurox Pty Ltd Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon
WO2013112605A2 (en) * 2012-01-23 2013-08-01 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
HUE056838T2 (hu) * 2012-08-21 2022-04-28 Sage Therapeutics Inc Allopregnanolon makacs epileptikus állapot kezelésére
EP2916846B1 (en) * 2012-11-09 2025-09-17 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
WO2014085668A1 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Anticonvulsant activity of steroids
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CA2973140C (en) * 2015-02-06 2025-09-16 Marinus Pharmaceuticals, Inc. Intravenous Ganaxolone Formulations and Their Use in the Treatment of Status Epilepticus and Other Epileptic Disorders
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
MX2018004376A (es) * 2015-10-16 2018-08-01 Marinus Pharmaceuticals Inc Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
RU2766155C2 (ru) 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
JP2019524816A (ja) 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics, Inc. てんかん性障害の処置のための方法および組成物
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019202640A1 (ja) 2018-04-16 2019-10-24 川崎重工業株式会社 ベルトコンベヤ
WO2020006596A1 (en) 2018-07-03 2020-01-09 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and methods of preparation
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2020123551A1 (en) * 2018-12-10 2020-06-18 Halo Science LLC Stable formulations of anesthetics and associated dosage forms
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
EP4072559A4 (en) 2019-12-06 2023-06-21 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399716A1 (en) * 1989-05-24 1990-11-28 Innovet, Inc. Hypoallergenic steroidal anesthetic/hypnotic compositions
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
WO2001070234A1 (en) * 2000-03-20 2001-09-27 Jurox Pty. Ltd. Anaesthetic composition
WO2004039426A3 (en) * 2002-10-31 2004-09-10 Transpharma Medical Ltd Transdermal delivery system for water insoluble drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
WO2002074200A1 (en) * 2001-03-20 2002-09-26 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
CA2631233C (en) * 2005-11-28 2011-11-08 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399716A1 (en) * 1989-05-24 1990-11-28 Innovet, Inc. Hypoallergenic steroidal anesthetic/hypnotic compositions
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
WO2001070234A1 (en) * 2000-03-20 2001-09-27 Jurox Pty. Ltd. Anaesthetic composition
WO2004039426A3 (en) * 2002-10-31 2004-09-10 Transpharma Medical Ltd Transdermal delivery system for water insoluble drugs

Also Published As

Publication number Publication date
AU2011207103B2 (en) 2013-03-21
NZ601255A (en) 2013-09-27
US20120316146A1 (en) 2012-12-13
KR20120136347A (ko) 2012-12-18
JP5930311B2 (ja) 2016-06-08
US8697678B2 (en) 2014-04-15
GB201201842D0 (en) 2012-03-21
SMT201700518T1 (it) 2018-01-11
EP2525798A4 (en) 2014-02-19
US8975245B2 (en) 2015-03-10
WO2011088503A1 (en) 2011-07-28
RS56576B1 (sr) 2018-02-28
CN102802635A (zh) 2012-11-28
GB2484244A (en) 2012-04-04
RU2574022C2 (ru) 2016-01-27
LT2525798T (lt) 2018-01-10
HUE035441T2 (en) 2018-05-02
GB2491491A (en) 2012-12-05
BR112012017800A2 (en) 2018-07-10
SI2525798T1 (en) 2018-01-31
RU2012134321A (ru) 2014-02-27
ZA201205370B (en) 2013-09-25
EP2525798B1 (en) 2017-08-09
US20140066417A1 (en) 2014-03-06
BR112012017800A8 (pt) 2018-08-14
CL2012002032A1 (es) 2012-12-21
NO2525798T3 (enExample) 2018-01-06
ES2646829T3 (es) 2017-12-18
DK2525798T3 (da) 2017-11-20
GB2484244B (en) 2012-10-31
JP2013517299A (ja) 2013-05-16
BR112012017800B1 (pt) 2020-12-08
CA2786762C (en) 2017-12-05
PL2525798T3 (pl) 2018-05-30
CY1119947T1 (el) 2018-12-12
SG181997A1 (en) 2012-08-30
HK1169031A1 (en) 2013-01-18
HRP20171699T1 (hr) 2018-01-26
GB201210657D0 (en) 2012-08-01
KR101747476B1 (ko) 2017-06-14
CA2786762A1 (en) 2011-07-28
AU2011207103A1 (en) 2012-07-26
GB2491491B (en) 2014-07-30
PT2525798T (pt) 2017-11-15
EP2525798A1 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
CN102802635B (zh) 麻醉药制剂
CN107261152B (zh) 包含环糊精和疏水性药物的可注射药物组合物的防腐方法
EP3556349B1 (en) Parenteral liquid preparation comprising carbamate compound
US8293749B2 (en) Injectable meclizine formulations and methods
AU2013200895C1 (en) Anaesthetic formulation
AU2014200491A1 (en) Anaesthetic formulation
HK1150553B (en) Pharmaceutical preparation comprising permethylated cyclodextrin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: DIAOQIAO PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: GOODCHILD INVESTMENT PTY LTD.

Effective date: 20140319

Free format text: FORMER OWNER: MONASH UNIV.

Effective date: 20140319

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140319

Address after: Vitoria, Australia

Applicant after: GOODCHILD INVESTMENTS PTY. LTD.

Address before: Vitoria, Australia

Applicant before: Goodchild Investments Pty. Ltd.

Applicant before: Monash Univ.

C14 Grant of patent or utility model
GR01 Patent grant